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In the same month that this manuscript was prepared,
newspapers had twice warned the public about the negative
aspects of alcohol consumption. South African drinkers
consume among the highest volumes of alcoholic beverages in
the world, at approximately 50 ml ethanol per drinker per day,1
making alcohol abuse one of South Africa’s top ten health and
social problems. Alcohol abuse is clearly associated with many
adverse health effects. In South Africa, fetal alcohol syndrome
(FAS) is of particular concern since the highest prevalence of
FAS in the world occurs in the Western Cape.2
While it is generally accepted that moderate, responsible
consumption of alcoholic beverages is not harmful, evidence is
emerging that there may even be health benefits. Moderate
drinking is now generally accepted as 10 - 35 g alcohol per day.
Evidence for the beneficial effects of the consumption of
alcoholic beverages on health may be derived from
epidemiological or experimental research. In the absence of a
controlled interventional study there should be strong evidence
from both avenues of investigation, and the benefits should
exceed the harm before public health recommendations can be
made to include the consumption of alcoholic beverages in
daily living. The purpose of this review is to provide some
background information on alcoholic beverages in general, but
with an emphasis on wine, and to describe the potential health
benefits of consuming alcoholic beverages. 
Alcoholic beverages
Studies examining the impact of alcoholic beverages on health
report the intake variably as units or grams of alcohol,
representing almost pure ethanol (ethyl alcohol), per day. A
unit of alcohol is defined as approximately 10 g ethanol, which
is equivalent to 1 drink (100 ml wine, 200 ml beer, 50 ml
fortified wine and 25 ml spirits). The fermentation process that
yields wine and beer is limited by the sugar content and the
alcohol concentration, since the latter will eventually inhibit
fermentation. Spirits have higher alcohol concentration because
of distillation. The ‘proof’ is a measure of the alcohol
concentration of alcoholic beverages, being twice the
percentage of alcohol by volume. Sherry and port are ‘fortified’
by additional alcohol. 
Wine essentially comprises water, ethanol, organic acids,
aldehydes, ketones, esters and many different phenolic
compounds that contain at least one hydroxyl group bound to
an aromatic ring. Red wines contain approximately 1 mg/ml of
phenols, about 5 - 10-fold more than white wines.
Approximately half of the total extractable phenols in grape
berries enter red wine. Fig. 1 shows the distribution of these
compounds in the grape berry. 
The bioavailability of the different phenolic compounds
varies widely. After the consumption of 10 - 100 mg of a single
phenolic compound, the maximum plasma concentration is
still less than 1 µmol/l, and urinary excretion varies from 0.3%
to 43% of the ingested mass of phenols, depending on the
particular phenol. The kinetics and plasma absorption of at
least 18 major polyphenols has been studied, but not linked
with health status.3
Wine polyphenols may broadly be divided into non-
flavonoids and flavonoids, with the latter making up the larger
group. Some of the individual chemical structures are depicted
in Fig. 2. Non-flavonoids include several classes such as the
hydroxycinnamic acids, the hydroxybenzoic acids and the
stilbenes, of which resveratrol is the best-characterised.
Flavonoids are organic molecules containing 15 carbon atoms
and 2 benzene rings (A and B). They may be classified into the
major classes, viz. flavanols, flavonols and anthocyanins.
Flavanols form the largest class and include monomeric
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Fig. 1. Diagram of a grape berry showing the
distribution of phenols.
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catechins and oligomeric and polymeric proanthocyanidins.
Procyanidins are oligomers of catechin and epicatechin. The
main simple flavonols are quercetin, kaempferol and myricetin.
The pharmacokinetics of alcohol metabolism have been
studied extensively. Alcohol dehydrogenase (ADH) reversibly
oxidises primary and secondary alcohols to their
corresponding aldehydes and ketones, much of which takes
place in the liver. Aldehyde dehydrogenase oxidises the
potentially reactive aldehydes to acetate which, once
conjugated to acetyl CoA, enters intermediary metabolism.
Genetic variations in ADH are known to influence alcohol
metabolism.4
Epidemiological evidence
In 1926 the first finding of a U-shaped association between all-
cause mortality and the consumption of alcoholic beverages
was reported by Raymond Pearl in a book titled Alcohol and
Longevity.5 Subsequently, a large number of epidemiological
studies also demonstrated this U- or J-shaped association,
indicating that moderate daily alcohol consumption results in a
significant reduction in mortality compared with abstinence or
excessive consumption. In the 1970s, when this apparent
benefit was confirmed,6 little attention was paid to these
results. It was not until the 1980s that the idea that moderate
consumption of alcohol might be beneficial to health led to
more systematic research. Epidemiological studies have shown
various benefits of moderate alcoholic beverage consumption,
with the vast majority of research results concerning the
benefits to vascular disease, in particular coronary heart
disease (CHD).7,8 Reports indicate a reduction of 30 - 50% in
vascular deaths. The ‘French Paradox’, a sometimes
controversial phenomenon described in 1992 by Renaud and
de Lorgeril,9 indicated a  lower rate of mortality from CHD
among the French compared with other developed countries,
despite similar dietary intakes in these countries. The putative
explanation was that the higher consumption of red wine
protected the French against heart disease. It has been
suggested, however, that the paradox may be due to
differences in data collection.  
Compared with abstention, moderate consumption of
alcohol, particularly wine, is associated with better cognitive
function and memory in subjects older than 65 years, and
higher bone mineral density among postmenopausal
women.10,11 Interestingly, moderate consumption of alcohol has
been reported to diminish the incidence of type 2 diabetes
mellitus12 and to reduce cardiovascular disease (CVD) in
established diabetic men and women.13,14 Various studies have
reported a reduction in the risk for total and ischaemic
strokes,15 but an increased risk of haemorrhagic stroke16 in
regular consumers of alcoholic beverages relative to abstainers
or occasional drinkers. The cumulative epidemiological
evidence summarised in Fig. 3 shows paradoxical results –
heavy drinkers suffer predominantly harmful results while
abstainers may fare less well than regular moderate drinkers in
the risk for CHD, stroke and total mortality. 
Fig. 2. Chemical structures of 
a) resveratrol, b) (+)-catechin, 
c) quercetin and d) malvidin-3-
glucoside (an anthocyanin).
Fig. 3. All-cause mortality, all-stroke and CHD risk in relation to
alcohol consumption. Data reflect the means and standard error of the
mean (SEM) from 7 all-cause, 11 all-stroke and 11 CHD studies,
respectively. 
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While epidemiological studies may associate alcoholic
beverage consumption with better health, it is difficult to prove
a causal relationship for several reasons. If a randomised
interventional study is not undertaken there may be a selection
bias for subjects who drink alcoholic beverages or even a
particular kind of alcoholic beverage. Because different diets
are often associated with the consumption of different alcoholic
beverages, it may be difficult to attribute the benefit to the
beverage. Wine consumption, for example, tends to be
associated with a higher intake of healthy food such as fruit,
vegetables, fish and olive oil. Additionally, in communities
with higher alcohol consumption, alcohol-related diseases may
be the reason for abstention. Furthermore, studies rely on self-
reported drinking, which may be underreported. Factors such
as gender, age, diet, smoking, economic status, social class,
ethnicity and education play a role in population health and
may therefore also be confounders in studies of the effects of
alcoholic beverages on health. Epidemiological studies should
ideally be carried out over a number of years because diseases
against which alcoholic beverages may confer protection, e.g.
CVD, develop slowly. Similarly, harmful effects may only be
evident in the long term. The changes in the body or health
outcomes that are being studied may require large sample
numbers to demonstrate an effect.   
Many reports support the proposal that wine has superior
effects on health relative to other alcoholic beverages.7,17,18 Some
studies have found that all alcoholic beverages have a positive
effect on the risk of CHD and mortality. Wine drinkers have
been found to have higher IQs, to smoke less, to exercise more,
to be better educated and to have higher socioeconomic status
than beer and spirit drinkers.19 The interpretation of reported
differences in health benefits of the different alcoholic
beverages should be viewed with caution until confounding
effects have been clearly ruled out or mechanistic differences
are evident. Although the balance of epidemiological evidence
is in favour of moderate consumption of alcoholic beverages
being conducive to good health, the central questions are still
largely unanswered.  It will be difficult to resolve the different
contributions of alcohol and phenols to health, whether wine is
superior to other alcoholic beverages or whether red wine is
superior to white wine, without resorting to interventional
studies or experimental evidence. 
The preceding discussion concerned favourable outcomes,
but some studies have failed to demonstrate any effect and
other studies have demonstrated detrimental effects. Data for
the effects of moderate alcohol consumption on cancer are
inconclusive, with some studies finding an increased risk of
cancers of the liver20 and upper digestive tract,21 particularly
after consumption of beer and spirits, and an increased risk of
breast cancer.22 Other studies20,23 found no increased risk of
breast, lung, bladder, prostate or ovarian cancers. A number of
epidemiological studies indicated an association between
alcohol consumption and increased blood pressure, with a
threshold dose of 20 - 30 g ethanol per day, above which the
pressure increases unequivocally. The acute and chronic effects
of excessive alcohol consumption on social and physical
wellbeing are well established although precise mechanisms
are not known.  
Experimental evidence
The influence on health of the ethanol in alcoholic beverages
has not been fully established and reports are contradictory.
Some studies have reported that it is the ethanol that is
responsible for the beneficial health effects rather than the
other characteristics of the beverage.24,25 This is contradicted by
other studies which demonstrate that the benefits of wine in
particular are derived from the non-alcoholic fraction,
suggesting that phenols and/or antioxidant activity confer(s)
the benefits.26,27 Red wine is often reported as having greater
antioxidant activity that can be attributed to its higher phenolic
content. However, some white wines that have an increased
extraction of grape skin polyphenols, have similar antioxidant
characteristics to red wines.28 An increase in the expression of
endothelial nitric oxide synthase (eNOS), an enzyme that
increases the production of NO, thereby enhancing
vasodilation, is associated with red wine but not with ethanol.
Ethanol-free red wine extracts have also been shown to
improve post-ischaemic ventricular function29 as well as to
inhibit ex vivo low-density lipoprotein (LDL) oxidation.30 Other
studies suggest that both the polyphenols and the alcohol in
red wine reduce the incidence of CHD, but by different
mechanisms.
Several additional potentially favourable effects of alcoholic
beverages are known. By preconditioning the heart, chronic
low-dose consumption of ethanol was found to maintain rat
hearts in a protected state; when ischaemia occurred, damage
measured by infarct size was reduced.31 Red and white wine
have been found to improve endothelial function in human
volunteers.32 High-density lipoprotein (HDL) concentrations
are significantly and consistently increased in humans after
consumption of alcoholic beverages, particularly red wine.33,34
Platelet aggregation promotes the development of
atherosclerosis by the formation of blood clots in arteries. A
number of studies35-37 have demonstrated the  anti-aggregating
effect on platelets of alcohol, red wine and dealcoholised red
wine. Moderate consumption of red wine has been found to
lower homocysteine concentrations in obese adults who have
an increased risk of vascular morbidity and mortality.38 Red
wine has bactericidal effects against Helicobacter pylori
(associated with gastric cancer) and Chlamydia pneumoniae
(which is associated with the development of CHD).39,40
Although not as effective, consumption of beer and spirits also
has this effect.41 Red wine has been found to inhibit growth of
various cancer cell lines such as breast, prostate and colorectal
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cancer.42-44 A recent finding45 suggests that resveratrol
influenced cell senescence favourably by mimicking the
calorie-restriction action of proteins called sirtuins. Congeners
that are more stable than resveratrol are being sought for
further study. 
Conclusions
Atherosclerosis is the dominant cause of morbidity and
mortality in developed countries and is rapidly rising in
developing countries.46 It is preferable to combat atherosclerosis
by means of preventive strategies involving lifestyle
modification, including a balanced diet, exercise, maintaining
an ideal body weight, and no smoking. Epidemiological
evidence suggests that moderate consumption (1 - 3 drinks per
day) of alcoholic beverages, particularly red wine, is associated
with an overall improvement in health, especially
cardiovascular health. Although the epidemiological
information is attractive, it is not adequately compelling for the
deliberate inclusion of alcoholic beverages in the lifestyle of
westernised subjects. Nevertheless, moderate consumption of
affordable alcoholic beverages in otherwise healthy subjects
will not increase the risk for disease, especially if it
accompanies a healthy lifestyle. The consumption of larger
amounts of alcohol is clearly ill-advised, and the consumption
of alcoholic beverages during pregnancy clearly places the
fetus at risk for developmental abnormalities.
Although several lines of experimental evidence suggest
mechanisms by which alcoholic beverages may reduce the risk
of vascular disease, there is inadequate understanding of
atherogenesis to know whether these mechanisms apply to any
given individual at risk and whether the alcoholic beverage
will be of direct benefit. Scientific research will hopefully
elucidate these mechanisms for specific intervention. Research
into the health benefits of alcoholic beverages may therefore
yield new avenues of treatment for atherosclerosis in the
future.
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